查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1931283

肽-PMO偶聯物市場按治療適應症、胜肽類型、最終用戶、給藥途徑和產品類型分類，全球預測，2026-2032年

Peptide-PMO Conjugates Market by Therapeutic Indication, Peptide Type, End User, Route Of Administration, Product Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年胜肽-PMO 偶聯物市值為 8,834 萬美元，預計到 2026 年將成長至 1.0694 億美元，複合年成長率為 15.74%，到 2032 年將達到 2.4592 億美元。

關鍵市場統計數據
基準年 2025 8834萬美元
預計年份：2026年 1.0694億美元
預測年份 2032 2.4592億美元
複合年成長率 (%) 15.74%

這篇權威的介紹清楚地向開發人員說明了胜肽-PMO偶聯物的分子基礎、臨床應用的先決條件以及臨床路徑的複雜性。

胜肽-PMO偶聯物融合了反義化學和基於胜肽的遞送技術，旨在克服傳統上限制寡核苷酸療法的細胞內屏障。磷醯二氨酸嗎啉代寡聚物（PMO）具有序列特異性功能，例如調節前體mRNA剪接和抑制翻譯，而肽偶聯則有助於細胞攝取、組織標靶化和核內體逃逸。該平台在系統生物分佈、穩定性和靶向細胞內遞送決定臨床療效的領域尤其有用。隨著治療方法的不斷發展，胜肽-PMO構建體的機制優勢——增強的細胞穿透性、調節的藥物動力學和潛在的標靶遞送能力——創造了將遺傳學見解與實用治療遞送相結合的全新治療機會。

近期的技術創新、監管變革和策略合作正在加速胜肽-PMO療法的臨床應用。

肽-PMO領域正受到多種相互作用因素的重塑，這些因素加速了轉化可行性和商業性化進程。胜肽工程的進步改進了細胞穿透基序，並引入了刺激響應型設計，從而實現了基於環境的有效載荷釋放；而PMO化學的創新則提高了核酸酶抗性並減少了脫靶相互作用。這些技術進步與我們對神經肌肉和神經退化性疾病生物目標的日益深入的理解相輔相成，使得更精準的外顯子跳躍和剪接調控策略成為可能。這些累積效應導致了候選藥物選擇標準的巨大轉變，而遞送載體的特性如今與序列設計同等重要。

深入分析2025年美國關稅將如何重塑胜肽-PMO研發領域的採購、製造地選擇和投資重點。

2025年美國關稅政策對複雜生物製藥和寡核苷酸藥物的原料採購、契約製造經濟效益和資金配置產生了切實的影響。胜肽合成所需的原料、PMO骨架建造所需的專用試劑以及偶聯和純化所需的專用耗材，從關稅區進口時可能面臨更高的到岸成本。這些壓力推高了早期研發和臨床生產規模化階段的產品總成本。為此，各機構正在重新評估籌資策略，優先考慮多元化的供應商網路和本地供應商，以降低關稅風險並減少交貨的不確定性。

將治療適應症、胜肽設計範式、最終用戶角色、給藥途徑和產品類型與開發和商業化優先事項聯繫起來，提供可操作的細分洞察。

細分研究闡明了胜肽-PMO偶聯物的科學機會與商業性可行性之間的交集。治療適應症決定了臨床設計和證據標準。針對肌萎縮側索硬化症 (ALS)、貝克氏肌肉萎縮症、Duchenne氏肌肉失養症和脊髓性肌肉萎縮症 (SMA) 的項目，各自具有獨特的目標組織、疾病進展時間線和終點預期。在神經肌肉適應症中，持續遞送至骨骼肌和運動神經元是一項核心技術要求，臨床開發路徑側重於與疾病嚴重程度和患者群體相適應的功能性和生物標記終點。

對美洲、歐洲、中東和非洲以及亞太地區的臨床能力、監管差異和生產重點進行比較區域分析，以指南策略發展。

區域趨勢將影響胜肽-PMO偶聯物的臨床開發路徑、監管互動和生產策略。在美洲，臨床試驗基礎設施和投資資本集中在擁有成熟神經肌肉和嚴重疾病網路的地區，有助於加快患者招募，並能獲得專門的臨床終點和註冊資訊。監管互動通常著重於針對存在未滿足醫療需求的嚴重疾病的快速核准途徑，而完善的專科醫療管道也有利於商業性市場進入計劃的實施。

公司層面的優勢（智慧財產權、平台技術、策略聯盟、製造夥伴關係）如何塑造胜肽-PMO開發中的競爭優勢與合作潛力

該領域的競爭不在於任何單一要素的優越性，而是整合胜肽設計、寡核苷酸化學、生產規模化和臨床開發等方面的專業知識。主要企業透過將深厚的反義寡核苷酸或PMO經驗與胜肽遞送技術結合，同時投資強大的CMC平台，以支援可重複的偶聯和分析控制，從而脫穎而出。胜肽專家和反義寡核苷酸開發人員之間的策略聯盟結合了互補的科學優勢，並在臨床前檢驗的關鍵節點上共用風險，從而加速候選藥物的研發。

為經營團隊和研發領導者提供實際有效的建議，以降低風險、最佳化夥伴關係並加速胜肽類藥物-PMO計畫的臨床和商業化準備。

根據整合胜肽設計、PMO化學和給藥途徑的目標，量身訂做早期開發策略。優先考慮能夠反映目標組織生物學特性的臨床前模型，這些模型應包含剪接調控和相關的標靶結合生物標記。早期投資轉化生物標記和自然史數據可以顯著縮短闡明作用機制的時間，並增強臨床研究人員和支付者的信心。同時，採用模組化的CMC開發方案，以便在不影響臨床交付時間表的情況下，迭代最佳化偶聯過程。

以清晰且可重複的調查方法為策略結論提供支撐，該方法整合了文獻綜述、專家訪談、監管分析和三角檢驗。

本研究綜合分析了同行評審文獻、監管申報文件、臨床試驗註冊資訊以及與胜肽化學、反義核酸治療藥物、臨床開發和生產領域專家的訪談結果。證據綜合優先考慮與神經肌肉疾病和神經退化性疾病相關的遞送、生物分佈、安全性和臨床終點直接相關的研究和監管文件。關鍵的定性資訊則透過與轉化科學家、臨床研究人員、CMC專家以及在偶聯寡核苷酸計畫方面擁有直接經驗的高階主管進行結構化訪談而獲得。

策略結論：透過優先考慮轉化檢驗、生產準備和合作模式，加速胜肽類藥物的臨床應用。

胜肽-PMO偶聯物處於靶向寡核苷酸活性和增強細胞內遞送的交匯點，為解決傳統上難以攻克的遞送難題提供了一條切實可行的途徑。此領域的成功取決於胜肽設計、PMO設計、分析嚴謹性和供應鏈韌性等方面的協調執行。相關人員應著重提供可重複的轉換證據，確保遞送創新技術的強大智慧財產權，並建立能夠共用技術風險、加速臨床檢驗的夥伴關係。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依治療適應症分類的胜肽-PMO偶聯物市場

  • 肌萎縮側索硬化症
  • 貝克氏肌肉萎縮症
  • Duchenne氏肌肉失養症
  • 脊髓性肌肉萎縮症

9. 依胜肽類型分類的胜肽-PMO偶聯物市場

  • 細胞滲透性
    • 來自 Antennapedia
    • 塔特衍生
    • 源自運輸
  • 刺激反應性
    • 酶響應
    • pH響應
    • 溫度響應性
  • 標靶化投放
    • 抗體偶聯型
    • 受體特異性

第10章 依最終用戶分類的胜肽-PMO偶聯物市場

  • 學術研究機構
  • 生技公司
  • 合約研究機構
  • 製藥公司

11. 依給藥途徑分類的胜肽-PMO偶聯物市場

  • 肌肉內注射
  • 靜脈注射
  • 皮下注射

12. 胜肽-PMO偶聯物市場（依產品類型分類）

  • 雙鏈
  • 單鏈

13. 各地區胜肽-PMO偶聯物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 胜肽-PMO偶聯物市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國肽-PMO偶聯物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國胜肽-PMO偶聯物市場

17. 中國肽-PMO偶聯物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • AmbioPharm, Inc.
  • Avidity Biosciences, Inc.
  • Bachem Holding AG
  • Bio-Synthesis, Inc.
  • Bio-Techne Corporation
  • Creative Biogene Corporation
  • Danaher Corporation
  • Entrada Therapeutics, Inc.
  • Gene Tools, LLC
  • GenScript Biotech Corporation
  • Ionis Pharmaceuticals, Inc.
  • Merck KGaA
  • Moderna, Inc.
  • Novartis AG
  • PeptiDream Inc.
  • PolyPeptide Group AG
  • QIAGEN NV
  • Sarepta Therapeutics, Inc.
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-7B550E008E07

The Peptide-PMO Conjugates Market was valued at USD 88.34 million in 2025 and is projected to grow to USD 106.94 million in 2026, with a CAGR of 15.74%, reaching USD 245.92 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 88.34 million
Estimated Year [2026] USD 106.94 million
Forecast Year [2032] USD 245.92 million
CAGR (%) 15.74%

An authoritative primer on peptide-PMO conjugates that clarifies the molecular rationale, translational prerequisites, and clinical pathway complexities for developers

Peptide-PMO conjugates represent a convergence of antisense chemistry and peptide-enabled delivery, designed to address intracellular barriers that have historically limited oligonucleotide therapies. Phosphorodiamidate morpholino oligomers (PMOs) carry sequence-specific capacity to modulate pre-mRNA splicing or inhibit translation, and conjugation to peptides enhances cellular uptake, tissue targeting, and endosomal escape. The platform is particularly relevant where systemic biodistribution, stability, and targeted intracellular delivery determine clinical efficacy. As modalities evolve, the mechanistic advantages of peptide-PMO constructs-improved cellular penetration, modulated pharmacokinetics, and potential for targeted delivery-create new therapeutic opportunities that bridge genetic understanding with practical therapeutic delivery.

Translational success demands rigorous alignment between peptide chemistry, PMO design, and route of administration. Intramuscular or intravenous delivery choices alter biodistribution and immunogenic exposure, while peptide type-whether cell penetrating, stimuli responsive, or targeted-shapes intracellular trafficking and specificity. Simultaneously, therapeutic indication informs acceptable safety margins and clinical endpoints; for example, indications for neuromuscular disorders require durable tissue penetration of skeletal muscle and motor neuron compartments. Consequently, development programs that integrate robust preclinical pharmacology, scalable conjugation manufacturing, and regulatory pathway planning will be positioned to advance clinical candidates more effectively.

This introduction frames why peptide-PMO conjugates are attracting multidisciplinary investment from chemistry, biology, and clinical development teams and sets the stage for deeper examination of market-relevant trends, segmentation dynamics, regulatory pressures, and actionable strategic priorities.

How recent technological innovations, regulatory evolution, and strategic partnerships are jointly accelerating translation of peptide-PMO therapeutics into clinical practice

The peptide-PMO landscape is being reshaped by several intersecting forces that accelerate translational feasibility and commercial interest. Advances in peptide engineering have improved cell-penetrating motifs and introduced stimuli-responsive designs that permit context-dependent payload release, while innovations in PMO chemistry have extended nuclease resistance and reduced off-target interactions. These technology advances are occurring in parallel with a richer understanding of target biology for neuromuscular and neurodegenerative disorders, enabling more precise exon-skipping and splice-modulation strategies. The cumulative effect is a step-change in candidate selection criteria where delivery vector properties are as critical as sequence design.

Regulatory pathways and payer expectations are evolving to accommodate novel oligonucleotide conjugates, emphasizing robust safety pharmacology, biodistribution data, and biomarker-driven proof of mechanism. At the same time, manufacturing scale-up has moved from boutique GMP efforts toward platform-enabled production models that emphasize reproducibility and cost controls, driven by collaborations between biotech developers and specialized contract manufacturers. Commercially, strategic partnerships and licensing arrangements are becoming the norm to combine peptide delivery know-how with antisense therapeutic expertise. These partnerships accelerate the de-risking of preclinical programs by aligning complementary capabilities.

Collectively, these shifts favor integrated programs that harmonize discovery, CMC, regulatory strategy, and commercial planning from early development. Organizations that adapt to this integrated model will capture efficiency advantages and shorten timelines from candidate validation to clinical proof of concept.

Detailed analysis of how 2025 United States tariff measures are reshaping procurement, manufacturing location decisions, and investment priorities across peptide-PMO development

Tariff measures introduced in the United States in 2025 have created tangible ripple effects across pharmaceutical ingredient sourcing, contract manufacturing economics, and capital allocation for complex biologic and oligonucleotide modalities. Raw materials used in peptide synthesis, specialty reagents for PMO backbone construction, and specialized consumables for conjugation and purification may be subject to increased landed costs when imported from tariff-affected jurisdictions. These pressures elevate the total cost of goods for early-stage development activities and for scaled clinical manufacturing runs. In response, organizations are reassessing procurement strategies to prioritize diversified vendor networks and near-shore suppliers to mitigate customs exposure and reduce delivery lead-time uncertainty.

Beyond direct procurement cost impacts, tariff-driven shifts influence strategic choices around manufacturing location and capacity investment. Some developers are accelerating qualification of domestic contract manufacturing partners to insulate critical supply chains from cross-border tariff volatility. Where feasible, vertical integration or multi-supplier redundancy is being implemented to preserve continuity for clinical programs with narrow manufacturing windows. Investors and corporate finance teams are also factoring tariff uncertainty into capital allocation models, prioritizing programs with clearer supply chain visibility or alternative sourcing options.

Regulatory compliance and customs classification complexity have increased administrative overhead for organizations with global procurement footprints, requiring enhanced tariff engineering and customs expertise. Consequently, development teams must coordinate more closely with procurement, legal, and regulatory affairs to maintain project timelines. The net effect is a strategic rebalancing that emphasizes supply chain resilience, supplier qualification diversity, and contractual protections to safeguard clinical progress and protect margins under tariff uncertainty.

Actionable segmentation insights that map therapeutic indications, peptide design paradigms, end-user roles, administration routes, and product types to development and commercialization priorities

Segmentation clarifies where scientific opportunity and commercial viability intersect for peptide-PMO conjugates. Therapeutic indication drives clinical design and evidence standards; programs aimed at Amyotrophic Lateral Sclerosis, Becker Muscular Dystrophy, Duchenne Muscular Dystrophy, and Spinal Muscular Atrophy each present unique target tissues, progression timelines, and endpoint expectations. For neuromuscular indications, durable delivery to skeletal muscle and motor neurons is a core technical requirement, and the clinical development pathway emphasizes functional and biomarker outcomes appropriate to disease severity and patient populations.

Peptide type defines delivery strategy and intracellular fate. Cell penetrating peptides remain central for broad intracellular uptake and include derivatives such as Antennapedia, Tat, and Transportan architectures, each with distinct uptake kinetics and safety profiles. Stimuli-responsive constructs introduce conditional release mechanisms-enzyme-responsive, pH-responsive, and temperature-responsive designs tailor payload activation to pathological microenvironments. Targeted delivery approaches focus on receptor engagement or antibody conjugation to improve tissue selectivity and decrease off-target exposure. These peptide classifications inform conjugation chemistry, dosing frequency, and immunogenicity considerations.

End user segmentation affects development timelines and collaboration models. Academic and research institutes typically drive early discovery and exploratory pharmacology, biotechnology companies advance translational proof of concept and investor-driven value creation, contract research organizations offer scalable preclinical and clinical execution capabilities, and pharmaceutical companies provide commercialization infrastructure and regulatory experience. Route of administration-intramuscular, intravenous, and subcutaneous-modulates systemic exposure, patient acceptability, and clinical site requirements. Product type differences between conjugated complexes, double stranded, and single stranded constructs influence manufacturing complexity, stability profiles, and analytical method development. Understanding these intersecting segments enables prioritization of R&D investment, selection of appropriate development partners, and alignment of clinical strategies with payer and regulatory expectations.

Comparative regional analysis of clinical capacity, regulatory nuance, and manufacturing priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific to guide strategic deployment

Regional dynamics shape clinical development pathways, regulatory interactions, and manufacturing strategies for peptide-PMO conjugates. In the Americas, clinical trial infrastructure and investor capital are concentrated in hubs with established neuromuscular and rare disease networks, which accelerates patient recruitment and provides access to specialized clinical endpoints and registries. Regulatory engagement often emphasizes expedited pathways for severe conditions with unmet need, and commercial market access planning benefits from well-developed specialty care channels.

Europe, Middle East & Africa presents a heterogeneous environment with variable regulatory expectations and reimbursement mechanisms. Several European regulatory authorities emphasize robust comparative effectiveness and health technology assessment evidence, shaping trial design and evidence generation strategies. Regional collaboration for rare disease registries and cross-border clinical networks can facilitate multi-country studies, but sponsors must plan for divergent reimbursement timelines and pricing pressures across jurisdictions.

Asia-Pacific presents rapid growth in clinical research capacity, an expanding pool of manufacturing talent, and diverse regulatory pathways that range from mature frameworks to rapidly evolving systems. Several countries in the region are investing in biotech manufacturing infrastructure and life sciences R&D incentives, creating attractive options for clinical manufacturing and regional trial execution. Each region's strengths inform strategic decisions about where to site trials, establish manufacturing partnerships, and prioritize market-entry sequencing to optimize clinical timelines and long-term access.

How company-level strengths in IP, platform engineering, strategic alliances, and manufacturing partnerships shape competitive advantage and partnership potential in peptide-PMO development

Competitive dynamics in this space are less about single-factor dominance and more about integrative capabilities across peptide design, oligonucleotide chemistry, manufacturing scale-up, and clinical development expertise. Leading organizations distinguish themselves by combining deep antisense or PMO experience with peptide delivery know-how, while also investing in robust CMC platforms that support reproducible conjugation and analytical control. Strategic alliances between peptide specialists and antisense developers accelerate candidate progress by pairing complementary scientific strengths and sharing risk across preclinical validation milestones.

Intellectual property around novel peptide motifs, conjugation chemistries, and delivery platforms is a material differentiator. Companies with well-constructed patent estates around specific cell-penetrating sequences or stimuli-responsive linkers can secure competitive moats that encourage licensing and partnership opportunities. At the same time, cross-licensing and co-development agreements have emerged as pragmatic approaches to bring complex candidates into clinical testing more quickly while leveraging established commercial channels.

Operationally, companies that have established relationships with specialized contract development and manufacturing organizations and that demonstrate clear scale-up pathways for conjugated oligonucleotides reduce execution risk. Additionally, firms that invest in translational biomarker programs and robust natural history studies enhance their ability to design efficient clinical trials and to engage payers with mechanistic evidence. The most successful organizations balance proprietary science with collaborative business models to optimize both innovation velocity and commercial feasibility.

High-impact, pragmatic recommendations for executives and R&D leaders to de-risk peptide-PMO programs, optimize partnerships, and accelerate clinical and commercial readiness

Align early development strategies around integrative objectives that combine peptide design, PMO chemistry, and route-of-administration decisions. Prioritize preclinical models that reflect target tissue biology and that include relevant biomarkers of splice modulation or target engagement. Early investment in translational biomarkers and natural history data can materially shorten time to clear proof-of-mechanism signals and increase confidence among clinical investigators and payers. Concurrently, adopt modular CMC development plans that allow iterative optimization of conjugation processes without disrupting clinical supply timelines.

Diversify supplier networks and qualify multiple manufacturing partners to mitigate tariff and logistics risks, and consider near-shore or regional manufacturing options to improve supply resilience. Seek strategic partnerships that pair peptide delivery expertise with antisense development capabilities to share technical risk and to accelerate clinical candidate advancement. Negotiate licensing and co-development terms that preserve sufficient upside while ensuring access to essential platform IP and manufacturing know-how.

Engage proactively with regulatory authorities to validate nonclinical packages, biodistribution expectations, and safety monitoring frameworks. Incorporate payers and HTA considerations early by documenting meaningful clinical benefit and health economics implications of targeted delivery approaches. Finally, build organizational capabilities in analytic method development and stability testing specific to conjugated oligonucleotides to de-risk late-stage development and support confident commercialization readiness.

A clear, reproducible research methodology that integrates literature review, expert interviews, regulatory analysis, and triangulated validation to underpin strategic conclusions

This research synthesized evidence from a comprehensive review of peer-reviewed literature, regulatory filings, clinical trial registries, and primary interviews with domain experts across peptide chemistry, antisense therapeutics, clinical development, and manufacturing. Evidence synthesis prioritized studies and regulatory documents that directly address delivery, biodistribution, safety, and clinical endpoints relevant to neuromuscular and neurodegenerative indications. Primary qualitative input was obtained through structured interviews with translational scientists, clinical investigators, CMC specialists, and senior executives who have direct experience with conjugated oligonucleotide programs.

Analytic rigor was maintained by triangulating qualitative inputs with published pharmacology data and with publicly available regulatory guidance. The methodology incorporated a gap analysis to identify where preclinical models, assay standardization, or manufacturing controls required additional focus. Where possible, findings were validated against multiple expert perspectives to reduce single-source bias and to ensure practical relevance to program execution. Assumptions used to derive strategic implications were explicitly documented and stress-tested through scenario analysis that considered supply chain disruption, regulatory variation across regions, and differing commercialization pathways.

This methodological approach produces insights that are actionable for developers and investors by combining empirical evidence with practitioner-informed judgment while maintaining transparency about sources and the limitations of available data.

A strategic conclusion that prioritizes translational validation, manufacturing readiness, and collaborative models to accelerate peptide-PMO clinical impact

Peptide-PMO conjugates occupy a promising intersection of targeted oligonucleotide activity and enhanced intracellular delivery, offering tangible routes to address historically intractable delivery challenges. Success in this field hinges on coordinated execution across peptide engineering, PMO design, analytical rigor, and supply chain resilience. Stakeholders should focus on delivering reproducible translational evidence, securing robust IP around delivery innovations, and building collaborative partnerships that accelerate clinical validation while sharing technical risk.

Immediate priorities for developers include establishing translational biomarkers, qualifying manufacturing partners with conjugation expertise, and proactively addressing regional regulatory nuances to support multi-jurisdictional development strategies. For investors and corporate strategy teams, the emphasis should be on backing integrated platforms with clear CMC pathways, validated delivery mechanisms, and demonstrable clinical proof of concept in target indications. By concentrating on these pragmatic levers-translational validation, manufacturing readiness, and strategic collaboration-organizations can move promising peptide-PMO candidates toward meaningful clinical impact with minimized execution risk.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Peptide-PMO Conjugates Market, by Therapeutic Indication

  • 8.1. Amyotrophic Lateral Sclerosis
  • 8.2. Becker Muscular Dystrophy
  • 8.3. Duchenne Muscular Dystrophy
  • 8.4. Spinal Muscular Atrophy

9. Peptide-PMO Conjugates Market, by Peptide Type

  • 9.1. Cell Penetrating
    • 9.1.1. Antennapedia Derived
    • 9.1.2. Tat Derived
    • 9.1.3. Transportan Derived
  • 9.2. Stimuli Responsive
    • 9.2.1. Enzyme Responsive
    • 9.2.2. PH Responsive
    • 9.2.3. Temperature Responsive
  • 9.3. Targeted Delivery
    • 9.3.1. Antibody Conjugated
    • 9.3.2. Receptor Specific

10. Peptide-PMO Conjugates Market, by End User

  • 10.1. Academic And Research Institutes
  • 10.2. Biotechnology Companies
  • 10.3. Contract Research Organizations
  • 10.4. Pharmaceutical Companies

11. Peptide-PMO Conjugates Market, by Route Of Administration

  • 11.1. Intramuscular
  • 11.2. Intravenous
  • 11.3. Subcutaneous

12. Peptide-PMO Conjugates Market, by Product Type

  • 12.1. Double Stranded
  • 12.2. Single Stranded

13. Peptide-PMO Conjugates Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Peptide-PMO Conjugates Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Peptide-PMO Conjugates Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Peptide-PMO Conjugates Market

17. China Peptide-PMO Conjugates Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Agilent Technologies, Inc.
  • 18.6. AmbioPharm, Inc.
  • 18.7. Avidity Biosciences, Inc.
  • 18.8. Bachem Holding AG
  • 18.9. Bio-Synthesis, Inc.
  • 18.10. Bio-Techne Corporation
  • 18.11. Creative Biogene Corporation
  • 18.12. Danaher Corporation
  • 18.13. Entrada Therapeutics, Inc.
  • 18.14. Gene Tools, LLC
  • 18.15. GenScript Biotech Corporation
  • 18.16. Ionis Pharmaceuticals, Inc.
  • 18.17. Merck KGaA
  • 18.18. Moderna, Inc.
  • 18.19. Novartis AG
  • 18.20. PeptiDream Inc.
  • 18.21. PolyPeptide Group AG
  • 18.22. QIAGEN N.V.
  • 18.23. Sarepta Therapeutics, Inc.
  • 18.24. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PEPTIDE-PMO CONJUGATES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PEPTIDE-PMO CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PEPTIDE-PMO CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY BECKER MUSCULAR DYSTROPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY BECKER MUSCULAR DYSTROPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY BECKER MUSCULAR DYSTROPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ANTENNAPEDIA DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ANTENNAPEDIA DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ANTENNAPEDIA DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TAT DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TAT DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TAT DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TRANSPORTAN DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TRANSPORTAN DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TRANSPORTAN DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ENZYME RESPONSIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ENZYME RESPONSIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ENZYME RESPONSIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PH RESPONSIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PH RESPONSIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PH RESPONSIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TEMPERATURE RESPONSIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TEMPERATURE RESPONSIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TEMPERATURE RESPONSIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ANTIBODY CONJUGATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ANTIBODY CONJUGATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ANTIBODY CONJUGATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY RECEPTOR SPECIFIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY RECEPTOR SPECIFIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY RECEPTOR SPECIFIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY DOUBLE STRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY DOUBLE STRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY DOUBLE STRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY SINGLE STRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY SINGLE STRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY SINGLE STRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. GCC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. GCC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 169. GCC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 170. GCC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 171. GCC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. GCC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. GCC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. G7 PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. G7 PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. G7 PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 196. G7 PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 197. G7 PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 198. G7 PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. G7 PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. G7 PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. NATO PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 203. NATO PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. NATO PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 205. NATO PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 206. NATO PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 207. NATO PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. NATO PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. NATO PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES PEPTIDE-PMO CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA PEPTIDE-PMO CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)